Auspex Pharmaceuticals Announces Positive Results from Clinical Study of SD-254, A Next-Generation Potential Treatment for Depression  
10/23/2008 9:10:55 AM

VISTA, Calif.--(BUSINESS WIRE)--Auspex Pharmaceuticals, a developer of next-generation medicines with improved safety and performance through the targeted deuteration of clinically validated drugs, today announced positive results from its Phase 1 clinical trial evaluating SD-254, a Selective Serotinin-Norepinephrine Reuptake Inhibitor (SNRI). Auspex is developing SD-254, a deuterium-substituted version of venlafaxine, for the treatment of Major Depressive Disorder.